Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Non-Current Assets for 14 consecutive years, with $130.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 62.51% year-over-year to $130.8 million, compared with a TTM value of $365.7 million through Dec 2025, up 10.12%, and an annual FY2025 reading of $76.4 million, down 0.53% over the prior year.
  • Non-Current Assets was $130.8 million for Q4 2025 at Enanta Pharmaceuticals, up from $76.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $130.8 million in Q4 2025 and bottomed at $38.2 million in Q4 2023.
  • Average Non-Current Assets over 5 years is $77.2 million, with a median of $74.3 million recorded in 2022.
  • Peak annual rise in Non-Current Assets hit 224.03% in 2021, while the deepest fall reached 64.3% in 2021.
  • Year by year, Non-Current Assets stood at $113.6 million in 2021, then plummeted by 43.83% to $63.8 million in 2022, then crashed by 40.16% to $38.2 million in 2023, then surged by 110.75% to $80.5 million in 2024, then skyrocketed by 62.51% to $130.8 million in 2025.
  • Business Quant data shows Non-Current Assets for ENTA at $130.8 million in Q4 2025, $76.4 million in Q3 2025, and $78.3 million in Q2 2025.